Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Launches Its Largest Cannabinoid Research Program
The R&D program will focus on the proprietary Lexaria DehydraTECH delivery technology with the purpose of enhancing it further Results could contribute to new patent filings in the future; in addition, the program will examine more extensively the way DehydraTECH-enabled CBD outperforms generic CBD Lexaria-designed nanotech enhancements will also be included in the program Biotechnology company and drug delivery platform innovator Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) is launching its largest cannabinoid research and development program to date. The program consists of 11 separate animal studies, according to a company press release (http://cnw.fm/YZd5X). The Lexaria in vitro study design was…